Using Obesity Drugs? Potential Vision Loss Disorder Linked To Novo Nordisk's Ozempic And Wegovy, Study Finds
Portfolio Pulse from Vandana Singh
A new study has found a potential link between Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, and a serious eye condition called nonarteritic anterior ischemic optic neuropathy (NAION), which can lead to vision loss. The study showed that individuals with diabetes or obesity who were prescribed semaglutide had a significantly higher risk of developing NAION compared to those using non-GLP-1 drugs. However, the study has limitations and does not establish causality.
July 03, 2024 | 4:41 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk's GLP-1 drugs, Ozempic and Wegovy, have been linked to a serious eye condition, NAION, in a new study. This has led to a 3.85% drop in NVO shares. The study found a significantly higher risk of NAION in patients with diabetes or obesity who were prescribed semaglutide. However, the study has limitations and does not establish causality.
The study's findings have raised concerns about the safety of Novo Nordisk's GLP-1 drugs, leading to a decline in the company's stock price. The significant increase in the risk of NAION among semaglutide users, despite the study's limitations, is likely to impact investor sentiment negatively in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100